87 results about "Molecular imaging" patented technology

The invention belongs to the technical field of biological medicine and electronic information technology, and discloses an atherosclerosis model based on nano-molecule magnetic resonance imaging and a machine learning algorithm, a nano-targeting probe and application of the atherosclerosis model based on the nano-molecule magnetic resonance imaging and the machine learning algorithm. A high-resolution MRI image capable of specifically displaying foam macrophage distribution in the plaque is obtained; then, image omics features are extracted from the images, a machine learning model which is constructed based on the features and verified by pathological labels is adopted for analysis, and finally an objective and quantitative plaque vulnerability score is output. According to the model disclosed by the invention, an objective and quantitative risk score can be output by fusing nano-targeted molecular imaging and machine learning, and accurate and reliable quantification of plaque vulnerability is realized. According to the invention, through systematic integration of targeted molecular imaging and machine learning, significant technical progress is brought.

A detector system for molecular imaging of a radionuclide comprises a 3D semiconductor detector comprising a plurality of sensor stacks of sensors made of a semiconductor material having an average atomic number Z below 40. A read-out circuitry connected to the pixels is configured to output, for each interaction induced by an incident gamma ray in the detector, a signal representative of a time, a position and an energy of the interaction in the detector. The interactions in the detector belonging to a same event induced by the incident gamma ray are predicted based on the output signals and used to estimate a direction of the incident gamma ray and reconstruct an image based on the estimated directions of incident gamma rays.

The invention relates to the technical field of tumor molecular imaging, nuclear medicine diagnosis and targeted therapy, and discloses a Trop2-targeted polypeptide, a Trop2-targeted molecular probe and application of the Trop2-targeted polypeptide and the Trop2-targeted molecular probe. The polypeptide can be coupled with different imaging elements to construct molecular probes or radiopharmaceuticals for tumor targeted imaging, so that noninvasive visual detection on the Trop2 expression level in tumor tissues is realized. The probe can specifically recognize Trop2 positive solid tumors, and a new technical means is provided for noninvasive diagnosis and dynamic monitoring of various Trop2 high-expression tumors such as pancreatic cancer, lung cancer, breast cancer and thyroid cancer. The probe disclosed by the invention has the advantages of simple preparation process, low cost, high specificity and stability, short imaging period, low radiation dosage, easiness in clinical transformation and the like, and has a wide application prospect in precise diagnosis and individualized treatment of tumors.

The invention provides a molecular probe targeting EDB-FN as well as a preparation method and application of the molecular probe. The structural formula of the molecular probe targeting EDB-FN is shown in the specification, according to the molecular probe targeting EDB-FN, the probe is based on a cyclic peptide probe with Lys-Glu side chain lactam bridge conformation fixed, the connection mode of a DOTA chelating agent is optimized, and the clinical transformation bottlenecks that an existing probe is poor in stability, low in affinity, insufficient in targeting specificity, poor in diagnosis and treatment integration compatibility and the like are solved. The probe can be used for early diagnosis and molecular imaging research of tumors, and provides a reliable basis for tumor malignancy degree evaluation and treatment effect monitoring.

The application discloses a polypeptide for targeted recognition of a neuroendocrine tumor marker INSM1 and products and applications thereof, and belongs to the fields of molecular imaging and protein polypeptide drug engineering. Specifically, the application relates to development of a polypeptide with high affinity and specificity to a neuroendocrine tumor marker insulinoma-associated protein 1 (INSM1). The application discloses an amino acid sequence of the polypeptide and related applications. The polypeptide is used for labeling and preparation of a polypeptide probe, can be specifically combined with the INSM1 protein, and can be used for in-vivo and in-vitro imaging of neuroendocrine tumors, so as to overcome a diagnosis difficulty caused by a hidden onset of the neuroendocrine tumor and realize early positioning and qualitative diagnosis.

The invention discloses an application of a tumor-associated macrophage targeting nanoprobe in ultrasensitive magnetic resonance molecular imaging of in-vivo in-situ lung cancer. The tumor-associated macrophage targeting nanoprobe prepared by the method provided by the invention is loaded with water-insoluble supramolecular celopphane, so that Xe'molecular cage 'celopphane can be uniformly dispersed in water and a biological system, and is used for in-vivo hyperpolarized 129Xe magnetic resonance imaging. According to the nanoprobe, mannose modification is carried out on the surface of the nanoprobe, so that the nanoprobe can effectively target tumor-related macrophages in a tumor area, and targeted detection of in-situ lung cancer tumors is realized; the surface of the nanoprobe is subjected to near-infrared fluorescence molecular modification, so that fluorescence / magnetic resonance bimodal detection of solid tumors can be realized. In combination with the advantage that local drug concentration can be improved by pulmonary drug delivery, a strong 129Xe magnetic resonance signal of the developed probe can be directly detected in vivo, and in-vivo 129Xe magnetic resonance molecular imaging is realized on an in-situ lung cancer model mouse through a direct sampling imaging mode.

The present invention pertains to the field of protein engineering, molecular imaging, molecular diagnostics, and biopharmaceutics. Provided herein are six unique Proteimer protein scaffolds (TEX-S2 / S3, TEX-S4, YTHDF3, PUM, DARPin, and Aca2) that demonstrate specificity and affinity comparable to antibodies across a broad range of therapeutic targets. Methods and protocols are provided for generating non-native protein aptamers, Proteimers, which are capable of binding to a diverse set of targets, including RNA, DNA, proteins, post-translational modifications, peptides, small molecules, and prosthetic groups. This platform supports the creation of biotherapeutic aptamers from Proteimer scaffolds for the treatment of various diseases.

The application belongs to the technical field of biological medicine and nanomaterials, and particularly relates to a method for enhancing multi-nuclear magnetic resonance signals based on lipid nanoparticle loaded with hole banana. 129 Xe molecular imaging and related biomedical applications provide a new technical path.

A programmed cell death ligand 1 (PD-L1) targeting polypeptide, a molecular imaging probe, and a use thereof are provided. The PD-L1 targeting polypeptide includes any one of the following polypeptides: (1) a polypeptide shown in at least one of SEQ ID NO: 1 to SEQ ID NO: 9; and (2) a polypeptide that is derived from an amino acid sequence of (1) through a substitution and / or a deletion and / or an addition of one or more amino acid residues and has the same function as the amino acid sequence. The magnetic resonance molecular imaging probe based on the PD-L1 targeting polypeptide enables the early diagnosis and evaluation of a tumor and an immune-mediated myocardial injury.

Disclosed in the present invention are a simple phenolic acid derivative- and rosmarinic acid derivative-based multimodal imaging probe and a use thereof. The multimodal imaging probe of the present invention has a structure selected from those represented by formulas (I to III). By subjecting phenolic acids such as danshensu, caffeic acid, ferulic acid, and rosmarinic acid to derivatization modification and by means of molecular imaging technology, the present invention realizes in vivo tracing and imaging of diseases such as various tumors (liver cancer, pancreatic cancer, and breast cancer), stroke, myocardial infarction, and acute kidney injury, and achieves in vivo and in vitro high-contrast imaging, real-time monitoring, and qualitative and quantitative evaluation. Moreover, the probe of the present invention itself has good metabolic properties and targeting performance, is simple to prepare and low in cost, and has broad clinical application prospects.

The application belongs to the technical field of molecular imaging and nanobody of tumor diagnosis and treatment, and discloses a Trop2 targeted nanobody fluorescent probe and a preparation method and application thereof. The nanobody T4 or ABDT4 capable of specifically recognizing TROP2 is connected with near-infrared two-region fluorescent dye through a chemical coupling mode to obtain a nanobody fluorescent probe with TROP2 targeting capability. The application realizes selective recognition at a molecular level by introducing the nanobody capable of specifically recognizing TROP2, which is helpful to improve the fluorescent contrast between tumors and normal tissues. Stable probe products are obtained through a controllable coupling and purification process, which is beneficial to repeated preparation and subsequent popularization and application.

1. The name of the design product: single photon emission and X-ray computed tomography system. 2. The use of the design product: functional and structural imaging, a nuclear medicine molecular imaging device integrating SPECT / CT multiple modalities three-dimensional medical image imaging and processing functions. 3. The design points of the design product: in shape. 4. The picture or photo that best shows the design points: perspective view.

The invention discloses a radionuclide-labeled isoindole-piperidinedione derivative and application thereof, and the structural formula of the radionuclide-labeled isoindole-piperidinedione derivative is shown in the specification. E3 ubiquitin ligase key protein CRBN is used as a new target for nuclear medicine molecular imaging research; dynamic expression of CRBN in a tumor microenvironment is accurately described by constructing a targeted molecular probe with an isoindole-piperidinedione parent nucleus structure, imaging guidance is provided for clinically and accurately screening benefited people and predicting the therapeutic effect of targeted CRBN, and imaging examples are also provided for researching dynamic expression of other key proteins in a ubiquitination system.

A detector system for molecular imaging of a radionuclide comprises a 3D semiconductor detector comprising a plurality of sensor stacks of sensors made of a semiconductor material having an average atomic number Z below 40. A read-out circuitry connected to the pixels is configured to output, for each interaction induced by an incident gamma ray in the detector, a signal representative of a time, a position and an energy of the interaction in the detector. The interactions in the detector belonging to a same event induced by the incident gamma ray are predicted based on the output signals and used to estimate a direction of the incident gamma ray and reconstruct an image based on the estimated directions of incident gamma rays.

The application discloses a kind of composite super-resolution ultrasonic molecular imaging method and related equipment, belong to ultrasonic imaging technical field, by obtaining high frame rate ultrasonic contrast image and conventional ultrasonic contrast image sequence, high frame rate ultrasonic contrast image sequence is carried out super-resolution image reconstruction, obtains super-resolution blood vessel image, ultrasonic molecular imaging processing is carried out to conventional ultrasonic contrast image sequence, obtains ultrasonic molecular imaging image, to super-resolution blood vessel image and ultrasonic molecular imaging image is carried out composite super-resolution imaging processing, obtains composite super-resolution ultrasonic molecular imaging result, to the selective display of composite super-resolution ultrasonic molecular imaging result is carried out, and composite super-resolution molecular imaging parameter extraction and analysis can be simultaneously super-resolution visualized vascular structure and blood flow in imaging area and specific biomolecule or marker distribution, simultaneously obtain vascular structure information and hemodynamics and specific target distribution function information.

The invention relates to the technical field of medicinal chemistry, in particular to a quinazoline compound as well as a precursor, a derivative and application thereof. The quinazoline compound provided by the invention has excellent precursor chemical stability and in-vivo metabolism stability, has relatively ideal imaging performance in a brain glioma model, and provides more reliable molecular imaging data for accurate diagnosis of cancers such as brain glioma and diagnosis and treatment of neuroinflammation related diseases; good clinical transformation potential is realized.

The application discloses a near-infrared carbon monoxide fluorescent probe and a preparation method and application thereof, wherein the probe has a structure shown in formula I; a fluorescent unit of the probe is constructed by connecting 2-pyridine acetonitrile and hydroxyl xanthene derivative through an olefin bond; the probe itself has weak fluorescence and can release strong near-infrared fluorescence signals after responding to carbon monoxide. The probe has the advantages of rapid response, high sensitivity and good selectivity. The probe can sensitively detect expression changes of endogenous carbon monoxide levels, realize direct diagnosis of pathological degrees of drug-induced liver injury, and realize visual evaluation of liver-protecting effects of active components of traditional Chinese medicines. The application integrates disease diagnosis and drug efficacy evaluation functions in a single probe system, and provides an efficient and intuitive molecular imaging tool for early warning of drug-induced liver injury and screening of liver-protecting components of traditional Chinese medicines.

A molecular imaging system for imaging of an awake and freely moving small animal includes a cuboid animal cage for one or more small animals and an enclosure for receiving the animal cage. The cuboid animal cage and the enclosure are transparent to the radiation emitted by the animal. At least part of the animal cage is transparent to light. A detector assembly including multiple molecular imaging detectors immediately surrounds the enclosure for detecting radiation emitted by the small animal. The molecular imaging detectors and the enclosure cover at least three sides of the cuboid animal cage in a U-shaped manner. A motion tracking system for optical tracking of position and orientation of the animal with optical detectors synchronizes movement and molecular images. A computation unit processes data registered by the detector assembly and the motion tracking system.

The invention relates to an F base modified von Willebrand factor vWF targeting aptamer and an application of the F base modified von Willebrand factor vWF targeting aptamer. Specifically, the invention provides an F base modified vWF targeting aptamer (AF-BT100), the F base modified vWF targeting aptamer comprises a nucleotide core sequence as shown in SEQ ID NO: 1, and the 5'end and the 3 'end are respectively connected with at least two artificial hydrophobic F bases. The invention also comprises a radionuclide-labeled molecular imaging probe [68Ga] Ga-NOTA-AF-BT100, which can realize specific PET imaging in the focus of atherosclerosis, carotid artery thrombosis and acute myocardial infarction. According to the invention, the integrated application of diagnosis and treatment of the pantovascular diseases based on the same vWF targeting aptamer is realized for the first time, and a new strategy is provided for accurate diagnosis and treatment of the pantovascular diseases.

The application discloses a novel radionuclide therapeutic drug targeting nucleolus DDX24 helicase and a preparation method and application thereof. 64 The Cu-DOTA-TDP-2 has good tumor targeting uptake specificity, and is expected to provide a precise molecular imaging method for esophageal squamous cell carcinoma and other DDX24 high-expression malignant tumors; the novel radionuclide targeted drug 177 The Lu-DOTA-TDP-2 has high radiochemical yield and specific activity, good chemical stability, high affinity for DDX24 helicase, and a simple and easy-to-operate preparation method, and can be used for the treatment of DDX24 high-expression malignant tumors; the novel radionuclide targeted drug 177 The Lu-DOTA-TDP-2 has excellent biological safety performance and good tumor inhibition effect in esophageal squamous cell carcinoma and other DDX24 high-expression malignant tumors.

The present invention pertains to the field of protein engineering, molecular imaging, molecular diagnostics, and biopharmaceutics. Provided herein are six unique Proteimer protein scaffolds (TEX-S2 / S3, TEX-S4, YTHDF3, PUM, DARPin, and Aca2) that demonstrate specificity and affinity comparable to antibodies across a broad range of therapeutic targets. Methods and protocols are provided for generating non-native protein aptamers, Proteimers, which are capable of binding to a diverse set of targets, including RNA, DNA, proteins, post-translational modifications, peptides, small molecules, and prosthetic groups. This platform supports the creation of biotherapeutic aptamers from Proteimer scaffolds for the treatment of various diseases.

The invention discloses a carbon nano molecular probe as well as a preparation method and application thereof, and belongs to the technical field of chemical biology. The carbon nano-molecular probe comprises carbon nano-particles, wherein the surfaces of the carbon nano-particles are connected with polypeptide, and the nitrogen end of the polypeptide is connected with fluorescent molecules. The nano-scale passive diffusion and fluorescence quenching properties of the carbon nano-particles are utilized, a polypeptide sequence which can be subjected to specific enzyme digestion and is labeled by specific fluorescence can be connected to the surfaces of the carbon nano-particles, molecular imaging is performed in immune cells, the biochemical environment and the curing state in the immune cells are monitored in real time, and cellular level immune drug screening is performed. The important application value is realized.

The invention belongs to the technical field of crossing of biological medicines and nano materials, and particularly relates to a multi-nuclear magnetic resonance signal enhancement method based on lipid nanoparticle loaded celestial soil. According to the preparation method disclosed by the invention, a high-efficiency and extensible supramolecular compound delivery platform is successfully constructed by encapsulating the monocarboxyl acuphane-A in the lipid nanoparticles LNPs, and a new technical path is provided for 129Xe molecular imaging and related biomedical application.

The invention provides a near-infrared NIR-II region fluorescence ratio probe based on tumor-associated neutrophil and application of the near-infrared NIR-II region fluorescence ratio probe. The nanoprobe is a rare earth doped down-conversion nanocrystal with a core-shell structure, the surface of the rare earth doped down-conversion nanocrystal is modified with a response unit and a targeting unit, and the response unit can release a fluorescence signal through enzymatic cleavage of neutrophil elastase; and the targeting unit is used for targeting a tumor microenvironment integrin receptor. The nanoprobe has high specificity and sensitivity, high anti-interference capability and self-calibration capability, can realize NIR-IIb region ratio imaging, provides a key basis for early curative effect judgment, achieves accurate individual stratification, fills the technical blank of cancer immunotherapy curative effect monitoring, and promotes the development of a tumor immune microenvironment molecular imaging technology.

This invention relates to the field of biomedical technology, and more particularly to a PD-L1-targeting polypeptide, its conjugate, and its applications. The polypeptide possesses the amino acid sequence shown in SEQ ID NO.1 or SEQ ID NO.2. This invention de novo designs a high-affinity PD-L1-targeting specific polypeptide. This polypeptide achieves extremely high affinity with the extracellular domain of the PD-L1 protein through its unique spatial conformation, exhibiting excellent targeting and recognition capabilities. The polypeptide provided by this invention can be conjugated with various modified molecules, such as radionuclides, and the constructed molecular imaging probe exhibits excellent tumor tissue targeting and enrichment capabilities, superior biocompatibility, and clear imaging contrast, enabling specific recognition of PD-L1-positive tumor lesions. It can be applied to clinical scenarios such as early precision diagnosis of tumors, screening of patients for immunotherapy, real-time monitoring of efficacy, and prognostic assessment, possessing significant translational medical value and broad application prospects.

The invention relates to the technical field of nano antibodies, in particular to an anti-CLDN6 nano antibody and application thereof. The invention provides an anti-CLDN6 nano antibody with high affinity and specificity, and a preparation method of the anti-CLDN6 nano antibody. The nano antibody can specifically recognize and combine CLDN6 targets of various solid tumors, including ovarian cancer, liver cancer, endometrial cancer, testicular cancer, gastric cancer and the like. The nano antibody provided by the invention can be used as a core recognition element and is used for constructing various treatment and diagnosis platforms such as chimeric antigen receptor T cells, NK cells, bispecific antibodies, antibody drug conjugates or molecular imaging probes. According to the technical scheme, the technical problem of lack of a high-specificity anti-CLDN6 nano antibody in the prior art can be solved, and an effective means is provided for immunotherapy of CLDN6 positive solid tumors.

The present application belongs to the technical field of ultrasonic molecular imaging and biomedical engineering, and particularly relates to a nano-ultrasound contrast agent for enhancing immunotherapy and a preparation method and application thereof. The nano-ultrasound contrast agent for enhancing immunotherapy provided by the present application is a novel ultrasonic nano-vesicle formed by loading a protein drug for blocking an immune checkpoint into a nano-carrier with a special composition. The nano-ultrasound contrast agent has high biological safety, small and uniform particle size, can be long-circulated in vivo, has good imaging effect on the extravascular field of a tumor, has good penetration, is highly targeted, has high drug utilization rate, can improve the delivery efficiency of a tumor immunotherapy drug and the immunotherapy effect, can realize tumor diagnosis and immunotherapy integration under ultrasonic guidance, and effectively solves the current problems of difficult tumor ultrasonic diagnosis, low tumor responsiveness of an immunotherapy drug, weak targeting, and inability to be regulated in vitro.

The application discloses a PET tracer targeting carbonic anhydrase IX (CA IX) and a preparation method and application thereof. 68 The tracer is prepared from a DOTA-bis-sulfonamide precursor compound and GaCl3 reaction. The tracer has high hydrophilicity, excellent stability in vitro and in vivo, low uptake of non-target organs and is mainly excreted through the kidney. Micro-PET / CT imaging shows that the tumor uptake is linearly correlated with the CA IX protein expression level measured by immunohistochemistry. Acute toxicity experiments show that the tracer has good biological safety. The application further provides a radiopharmaceutical composition containing the tracer and application of the tracer in preparation of a PET imaging agent for diagnosing CA IX positive tumors. The tracer has the advantages of high labeling efficiency, low background interference, accurate quantification and potential integration of diagnosis and treatment, and is suitable for precise molecular imaging of CA IX high expression tumors such as clear cell renal cell carcinoma and colorectal cancer.

The imaging device may be used for histological and / or molecular imaging of tissue samples. The imaging device may include one or more light sources. The one or more light sources generate one or more excitation beams directed to an excitation position focused on the sample to generate signals at the sample, and one or more interrogation beams directed to a detection position, where a portion of the one or more interrogation beams returning from the sample indicates at least some of the generated signals. The imaging device may include a photodetector configured to detect emission signals from the sample. The imaging device may generate an image of the sample using only pressure (photoacoustic) signals, only temperature (photothermal) signals, and / or both photoacoustic and photothermal signals from the generated signals.

The invention provides a neural stem cell differentiation process monitoring system for a living body and a construction method and application thereof, and belongs to the technical field of nuclear medicine molecular imaging. The invention provides a neural stem cell differentiation process monitoring system for a living body. According to the monitoring system, a TYR reporter gene is integrated into a genome of a neural stem cell through a recombinant virus vector, and the recombinant neural stem cell is obtained; after the recombinant neural stem cell is transplanted in the brain, the TYR reporter gene contained in the recombinant neural stem cell expresses tyrosinase in the recombinant neural stem cell, tyrosinase catalyzes tyrosine reaction to generate a tyrosine reaction product, and the tyrosine reaction product can be used for preparing the recombinant neural stem cell. The content of the tyrosine reaction product can be quantitatively determined through the PET probe of the targeted tyrosinase biosynthetic product, so that the in-vivo monitoring of the differentiation process of the transplanted neural stem cells in the brain is realized. The construction of the monitoring system provided by the invention provides an effective research tool for research on treatment of cerebral arterial thrombosis by regenerative medicine and neural stem cell transplantation.